Literature DB >> 9579711

Anti-inflammatory activity of macrolides: a new therapeutic potential?

M T Labro1.   

Abstract

The important role played by macrolides in the chemotherapy of infectious diseases is well established, but there is still much speculation about their anti-inflammatory potential. A review of in-vitro and ex-vivo studies reported in the literature shows that macrolides have potentially relevant immunomodulatory effects. In-vitro data suggest that erythromycin A derivatives have a direct effect on neutrophil function and the production of cytokines involved in the inflammation cascade. The ex-vivo results indicate that short-term administration of macrolides may enhance the immune response while long-term administration results in immunosuppression. Further research is required to improve our understanding of the therapeutic activity of macrolides.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9579711     DOI: 10.1093/jac/41.suppl_2.37

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  42 in total

1.  Cellular uptake of two fluoroketolides, HMR 3562 and HMR 3787, by human polymorphonuclear neutrophils in vitro.

Authors:  H Abdelghaffar; D Vazifeh; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 2.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 3.  Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin.

Authors:  André G Buret
Journal:  Can J Vet Res       Date:  2010-01       Impact factor: 1.310

4.  The anti-nociceptive potential of tilmicosin against chemical-induced but not thermal-induced pain in mice.

Authors:  A El-Mahmoudy; I Gheith
Journal:  Int J Immunopathol Pharmacol       Date:  2015-10-30       Impact factor: 3.219

5.  Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia.

Authors:  Bryan Z Wilson; Antonio Anzueto; Marcos I Restrepo; Mary Jo V Pugh; Eric M Mortensen
Journal:  Crit Care Med       Date:  2012-08       Impact factor: 7.598

6.  Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophils.

Authors:  D Vazifeh; A Bryskier; M T Labro
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

7.  Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.

Authors:  Liisa Törmäkangas; Hannu Alakärppä; Denise Bem David; Maija Leinonen; Pekka Saikku
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 8.  What's new in cystic fibrosis? From treating symptoms to correction of the basic defect.

Authors:  Marijke Proesmans; François Vermeulen; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2008-04-04       Impact factor: 3.183

9.  Ceftiofur regulates LPS-induced production of cytokines and improves LPS-induced survival rate in mice.

Authors:  Xinxin Ci; Hongyu Li; Yu Song; Na An; Qinlei Yu; Fanqin Zeng; Xuming Deng
Journal:  Inflammation       Date:  2008-12       Impact factor: 4.092

Review 10.  Macrolide antibiotics for cystic fibrosis.

Authors:  Kevin W Southern; Pierre M Barker; Arturo Solis-Moya; Latifa Patel
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.